文献速递血栓与止血

免疫性血小板减少症(ITP)的疾病负担:难治性ITP的特殊考量

Burden of immune thrombocytopenia (ITP): Special considerations for refractory ITP.
PubMed 文献 · Br J Haematol · 2023-01-01

本文讨论免疫性血小板减少症(ITP)患者的疾病负担,假设难治性ITP患者存在额外负担,包括疲劳更明显、二线和三线治疗副作用、对长期病程的焦虑、月经过多所致健康相关生活质量(HRQoL)受损及生育规划担忧。作者指出评估工具繁多致研究间比较困难,需标准化评估,且治疗低血小板计数和出血症状是否改善HRQoL尚无定论、已发表证据存在矛盾。

要点

  • 难治性ITP患者疲劳更明显,并有二线和三线治疗的额外副作用。
  • 难治性ITP患者对长期病程有额外焦虑,月经过多致HRQoL受损并有生育规划担忧。
  • HRQoL评估工具繁多致研究间比较困难,需标准化评估以便常规临床实施。

核心结论

  • 改善HRQoL是患者和医生的主要治疗目标,治疗难治性ITP时应特别考虑。
  • 治疗低血小板计数和出血症状是否对HRQoL有正面影响尚待观察,已发表证据存在矛盾。

研究设计与样本

  • 本文为关于ITP疾病负担的综述,聚焦难治性ITP的特殊考量。

主要发现

  • 难治性ITP患者疲劳更明显,并有二线和三线治疗的额外副作用。
  • 难治性ITP患者对长期病程有额外焦虑,月经过多致HRQoL受损并有生育规划担忧。
  • 研究者使用了众多工具评估HRQoL和疲劳,使研究间数据比较具有挑战性。
  • 治疗低血小板计数和出血症状是否对HRQoL有正面影响尚待观察,已发表证据存在矛盾。

关键数值与推荐

  • 需使用可在常规临床实践中轻松实施的疾病特异性或通用工具标准化评估。

临床怎么用

  • 应仔细评估和考虑难治性ITP患者的疾病负担。
  • 改善HRQoL是患者和医生的主要治疗目标,治疗难治性ITP时应特别考虑。

局限性

  • 研究者使用了众多工具评估HRQoL和疲劳,使研究间数据比较具有挑战性。
  • 治疗低血小板计数和出血症状是否对HRQoL有正面影响尚待观察,已发表证据存在矛盾。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

It is known that patients with immune thrombocytopenia (ITP) have fatigue and impairment of health-related quality of life (HRQoL). However, it is hypothesized that patients with refractory ITP have additional burdens that should be considered. Specifically, fatigue is more pronounced in patients with refractory disease, there are additional side effects from second- and third-line treatments, additional anxiety about the long-term course of the disease, impairment in HRQoL resulting from heavy menstrual bleeding and concerns related to family planning. The burden of disease, therefore, should be carefully assessed and considered in these patients. However, researchers have utilized numerous tools for evaluating HRQoL and fatigue, making comparison of data across studies challenging. There is a need to standardize assessment using either disease-specific or generic instruments that can be easily implemented in routine clinical practice. Additionally, whether treatment of low platelet count and bleeding symptoms will have a positive influence on HRQoL remains to be seen and published evidence is conflicting. Nevertheless, improvement of HRQoL is a major treatment goal for both patients and physicians and should be especially considered when treating patients with refractory ITP.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Rüfer A, Terrell DR. Burden of immune thrombocytopenia (ITP): Special considerations for refractory ITP. Br J Haematol. 2023. PMID: 37735553. doi:10.1111/bjh.19068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。